一年一度的欧洲肿瘤盛会ESMO于9月份顺利线上举行,虽受疫情影响,未再现往年万人共聚的盛况,但群研荟萃,各展风采,全球肿瘤进展竞相面世,堪称饕餮盛宴。而其中,有一项临床研究,因其独特的用药方案设计和结果,显得分外耀眼,这就是来自目前国内上市的二代ALK抑制剂塞瑞替尼ASCEND-8研究更新,针对亚洲人群对比450mg随餐用药与750mg空腹用药的临床疗效及安全性分析。在当前以“各类强化治疗追求高疗效”的大趋势下,为患者寻找到了巧用药物性质减量使用,副作用大减、疗效不减的新模式。具有高度的临床启发意义和实用性,让我们一起来看看ASCEND-8带来的亚洲人群数据。 一 ESMO对ASCEND-8塞瑞替尼研究的数据解读:疗效安全双重丰收! 二 塞瑞替尼挑战另一大硬核,症状性脑转/脑膜转移再攻破! 总 结 ![]() 金波 教授 中国医科大学 附属第一医院 肿瘤内科 副主任
声明:本文旨在传递医药前沿信息和研究进展,不构成对任何药物的商业推广或对诊疗方案的推荐。本文提及的部分药物和/或适应症尚未在中国获批,相关临床研究可能缺乏中国患者的数据。 本文版权归找药宝典所有,任何个人或机构转载需获得找药宝典授权,在授权范围内使用,并标注来源“找药宝典”。 文章转载、媒体合作请联系小编:p88128812 参考文献: 1.https://cslide./esmo2020/attendee/confcal_2/presentation/list?q=ceritinib 2. Julio Sánchez de Cos , M Agustín Sojo González, María Victoria Montero, et al. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer 2009 Jan;63(1):140-5. doi: 10.1016/j.lungcan.2008.04.013. Epub 2008 Jun 16. 3. Crinò L, Ahn MJ, De Marinis F, et al. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2[J]. J Clin Oncol. 2016 Aug 20;34(24):2866-73. 4. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study[J]. Lancet. 2017 Mar 4;389(10072):917-929. 5. https://oncologypro./meeting-resources/esmo-2019-congress/Results-of-the-ASCEND-7-phase-II-study-evaluating-ALK-inhibitor-ALKi-ceritinib-in-patients-pts-with-ALK-non-small-cell-lung-cancer-NSCLC-metastatic-to-the-brain 6. Y-L Wu , D Planchard , S Lu ,et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019 Feb 1;30(2):171-210. doi: 10.1093/annonc/mdy554. 7. D.W. Kim, R. Mehra, D.S.W. Tan, E. Felip, L.Q.M. Chow, D.R. Camidge, et al.Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial Lancet Oncol, 17 (2016), pp. 452-463 8. Shirish M Gadgeel , Alice T Shaw , Ramaswamy Govindan,et al. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Dec;34(34):4079-4085. doi: 10.1200/JCO.2016.68.4639. Epub 2016 Oct 31. |
|